Semaglutide vs. tirzepatide peptides: an evidence comparison
Semaglutide and tirzepatide are different peptide-based medicines with different receptor activity and product approvals. A useful comparison starts with the exact approved product and study population.
Their receptor activity differs
Semaglutide acts at the GLP-1 receptor. Tirzepatide acts at GIP and GLP-1 receptors. That distinction describes pharmacology; it does not select a treatment for an individual.
Trial results require context
Study populations, endpoints, follow-up, formulations and adverse-event reporting affect comparisons. Headline percentages should not be detached from the study design or used as a personal forecast.
Product authenticity is a separate question
Even strong clinical evidence for an approved medicine cannot authenticate an online vial. Product authorization, dispensing source, label and chain of custody still need verification.
Peptide questions
Which peptide is better for weight loss?
Peptely does not make individual treatment recommendations. A licensed clinician can interpret approved options in your clinical context.
Can COAs compare clinical effectiveness?
No. A COA reports analytical measurements for a sample; clinical trials evaluate outcomes in people.
Sources and further reading
Check a peptide certificate
Compare a real peptide COA with the lot, compound, analytical methods and laboratory record.
Start a peptide COA check